- Global Pharma News & Resources

Polyplus-transfection acquires Biowire to further expand into Asia-Pacific gene and cell therapy markets

Polyplus-transfection acquires Biowire to further expand into Asia-Pacific gene and cell therapy markets

Acquisition continues Polyplus’ global expansion plans for delivery of transfection reagent solutions to meet increasing global demand


Strasbourg, France, March 9, 2021 –Polyplus-transfection® SA, the leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, today announces it is acquiring the main assets of Biowire. Financial details were not disclosed. 


Biowire is a company specializing in supporting life sciences tool and reagent companies to expand into Asia-Pacific. Biowire was founded in 2011, and is based in Hong Kong with additional offices in Shanghai, Beijing, Tokyo, Kobe, Seoul and Kuala Lumpur. 


“Polyplus-transfection continues to experience exponential growth in demand for critical raw materials across the globe for ATMP development and manufacturing. As a result, Polyplus is continuing with its expansion plans internationally following the substantial growth investment from Warburg Pincus and ArchiMed last year.  Polyplus has just initiated construction of Vectura, Polyplus’ new 4,000m2 facility in France,” said Mario Philips, Chief Executive Officer of Polyplus-transfection. “Having worked with Biowire for a number of years, acquiring the company provides Polyplus with a wholly owned structure in China and a dedicated team across Asia-Pacific that has built both experience in revenue growth and connections with the supply chain, local services and cell and gene therapy companies throughout the region. This acquisition will enable Polyplus to increase its capability of satisfying the growing demand of the Asia cell and gene therapy markets for our products and services with our continued innovation.”


“Polyplus has been a client of Biowire for close to ten years. Both companies have worked closely with each other to drive Polyplus’s continuous growth in the region. Biowire has helped Polyplus achieve this specifically by developing access to Asia-Pacific academic and cell and gene therapy industrial markets,” said Bertrand Coissac, Founder and Managing Director of Biowire. “This acquisition is an opportunity for the Biowire team to join a unique industrial adventure while continuing to deliver superior services to our channel partners, researchers and manufacturers of cell and gene therapy across the whole region.” 


About Polyplus-transfection SA 

Polyplus-transfection® SA is the leading biotechnology company that supports Gene and Cell therapy, along with other biologics manufacturing and life science research with innovative nucleic acid transfection solutions. Polyplus-transfection’s strengths are 20 years of experience in manufacturing transfection solutions with tailored scientific and regulatory support to accelerate research and clinical development. Based on the Science Park close to Strasbourg (France), Polyplus-transfection offers an extensive and growing range of transfection reagents available worldwide. For more information, please visit the Polyplus-transfection web site at: 


About Biowire

Biowire is a service firm founded in 2011, based in Hong Kong and with offices in Shanghai, Beijing, Tokyo, Kobe, Seoul and Kuala Lumpur. Biowire’s mission is to support life science tool and reagent companies to boost their sales across the dynamic markets of cell and gene therapy research, development and manufacturing in Asia-Pacific. The company’s expertise lies in market entry strategy, development and execution, partnership management and sales generation. Its clients are among the hottest technology companies supplying the cell and gene therapy research and manufacturing markets.

Editor Details

Last Updated: 10-Mar-2021